

Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma



Paula Llabata¹, Yoichiro Mitsuishi^{2,3}, Peter S. Choi^{2,3}, Diana Cai^{2,3,4}, Joshua M. Francis^{2,3}, Manuel Torres-Diz¹, Namrata D. Udeshi³, Lior Golomb^{2,3}, Zhong Wu^{2,3}, Jin Zhou^{2,3}, Tanya Svinkina³, Estrella Aguilera-Jimenez⁵, Yanli Liu⁵, Steven A. Carr³, Montse Sanchez-Cespedes¹, Matthew Meyerson^{2,3,4}, and Xiaoyang Zhang⁵

ABSTRACT

Genomic analysis of lung adenocarcinomas has revealed that the *MGA* gene, which encodes a heterodimeric partner of the MYC-interacting protein MAX, is significantly mutated or deleted in lung adenocarcinomas. Most of the mutations are loss of function for MGA, suggesting that MGA may act as a tumor suppressor. Here, we characterize both the molecular and cellular role of MGA in lung adenocarcinomas and illustrate its functional relevance in the MYC pathway. Although MGA and MYC interact with the same binding partner, MAX, and recognize the same E-box DNA motif, we show that the molecular function of MGA appears to be antagonistic to that of MYC. Using mass spectrometry-based affinity proteomics, we demonstrate that MGA interacts with a noncanonical PCGF6-PRC1 complex containing MAX and E2F6 that is involved in gene repression, while MYC is not part of this MGA complex, in agreement with

previous studies describing the interactomes of E2F6 and PCGF6. Chromatin immunoprecipitation-sequencing and RNA sequencing assays show that MGA binds to and represses genes that are bound and activated by MYC. In addition, we show that, as opposed to the MYC oncoprotein, MGA acts as a negative regulator for cancer cell proliferation. Our study defines a novel MYC/MAX/MGA pathway, in which MYC and MGA play opposite roles in protein interaction, transcriptional regulation, and cellular proliferation.

Implications: This study expands the range of key cancer-associated genes whose dysregulation is functionally equivalent to MYC activation and places MYC within a linear pathway analogous to cell-cycle or receptor tyrosine kinase/RAS/RAF pathways in lung adenocarcinomas.

Introduction

Activation of the MYC pathway is a key driver for diverse cancer types. The *MYC* gene is frequently amplified in cancer cells, which results in its increased expression (1). Indeed, *CCND1*, *EGFR*, and *MYC* are the top three amplified oncogenes based on pan-cancer analysis of 10 different cancer types (2). Many other genomic events, such as chromosomal translocations and superenhancer amplifications, also activate *MYC* expression (3–6). The overexpressed MYC protein binds to and activates genes that are promoting cellular proliferation (7, 8). In addition, MYC is reported to activate genes that are involved in apoptosis, ribosomal biogenesis, metabolism

pathways, genome instability and immune escape, which are involved in tumorigenesis and metastasis (7–9).

The activity of the MYC protein is tightly regulated by a protein interaction network that is centered on the MAX protein (10). MYC interacts with MAX to form a heterodimeric complex, which is essential for MYC to recognize and bind to the E-box DNA sequence (CACGTG) that is enriched in gene promoter regions (11, 12). The dimerization of MYC and MAX is mediated through the interaction between their basic region/helix loop helix/leucine zipper (bHLHZ) domains (12). MYC activates gene expression through its association with histone acetyltransferase complexes, the bromodomain protein BRD4 and the transcriptional pause-release complex P-TEFb (13–16). In addition to MYC, MAX also heterodimerizes with another group of proteins containing bHLHZ domains—the MXD family of proteins, including MXD1–4 and MNT. Although the MXD/MAX and MNT/MAX complexes recognize the same E-box DNA sequence as MYC/MAX does, their bindings to DNA result into repression of target genes, which is due to their physical interaction with the repressive complex mSIN3 (17, 18).

MGA (MAX gene-associated protein) is a bHLHZ protein that has been reported to interact with MAX and to bind to the E-box DNA sequence (19). MGA, consisting of 3,065 amino acids, is the largest protein in the MAX-interacting protein family (10). In addition to the MAX-interacting bHLHZ domain, MGA contains a T-box domain at the N-terminus, which recognizes the Brachyury binding sequence, suggesting a MAX-independent mechanism for the DNA-binding ability of MGA (19). MGA represses expression of an *in vitro* MYC-driven luciferase reporter (19), suggesting that MGA may act as a suppressor of MYC target genes. Recent exome-sequencing efforts have revealed that the *MGA* gene is significantly mutated in lung adenocarcinoma and high-risk chronic lymphocytic leukemia (20, 21).

¹Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Barcelona, Spain. ²Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. ³Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts. ⁴Department of Pathology, Harvard Medical School, Boston, Massachusetts. ⁵Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Note: Supplementary data for this article are available at Molecular Cancer Research Online (<http://mcr.aacrjournals.org/>).

P. Llabata and Y. Mitsuishi contributed equally to this article.

Corresponding Authors: Xiaoyang Zhang, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112. Phone: 801-213-8410; E-mail: Xiaoyang.Zhang@hci.utah.edu; and Matthew Meyerson, Matthew_Meyerson@dfci.harvard.edu

Mol Cancer Res 2020;18:574–84

doi: 10.1158/1541-7786.MCR-19-0657

©2019 American Association for Cancer Research.

However, the biological role of MGA in those cancer types, particularly its functional link with the MYC pathway, is largely unknown.

Here, we show that the *MGA* gene is frequently subject to loss-of-function mutations and copy-number deletions in multiple cancer types. We characterize both the molecular and cellular role of MGA in lung adenocarcinoma cells. We integrate results from mass spectrometry-based affinity proteomics, chromatin immunoprecipitation-sequencing (ChIP-seq) and RNA sequencing (RNA-seq) approaches to study the gene regulation function of MGA, which reveals that MGA forms a gene repression complex with a noncanonical PCGF6-PRC1 complex and binds to and represses genes that are bound and activated by the MYC oncoprotein. Importantly, we show that, as opposed to MYC, MGA acts as a negative regulator of cancer cell proliferation, supporting its role as a tumor suppressor. Our study helps to elucidate

the role of MGA in the MYC oncogenic pathway and supports the definition of a MYC/MAX/MGA pathway that could serve as a potential therapeutic target in the future.


Materials and Methods

Genomic analysis of data from The Cancer Genome Atlas (TCGA)

We analyzed sequencing results of TCGA lung adenocarcinoma samples ($n = 507$) and samples from other cancer types on the Pan Cancer c-Bio portal (22, 23). We presented analyses of samples with *MYC* amplification, *MGA* homozygous deletions, or *MGA* loss-of-function mutations in lung adenocarcinoma in Fig. 1A and Supplementary Fig. S1.

Figure 1.

Genomic and proteomic analysis of MGA in lung adenocarcinomas. **A**, Mutation profile of *MGA* in lung adenocarcinomas. Missense (green dots) and truncating mutations (black dots) are highlighted. **B**, Immunoprecipitation-mass spectrometry (IP-Mass Spec) results in HEK293T cells (2 biological replicates). We identified proteins that are significantly enriched by the endogenous MGA antibody, relative to IgG control (adjusted $P < 0.05$). The proteins that are part of a noncanonical PRC1 (ncPRC1)—the PCGF6-PRC1 complex—are highlighted by red dots. **C**, Immunoprecipitation (IP) of MGA and IgG, followed by immunoblotting of MGA-interacting proteins in HEK293T, A549, and NCI-H23 cells.



Cell lines

Cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE) project (24) in 2016 and 2017. Cell line identities were verified by SNP genotyping using an Affymetrix SNP array as previously described in the CCLE project (24). Cells were tested negative for *mycoplasma* using the Lonza MycoAlert Mycoplasma Detection kit at July 2018. Cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS and 1% penicillin–streptomycin. Cells lines were passaged every 3 or 4 days and were used for functional assays within 3 months of passages post receipt.

Immunoprecipitation

We performed immunoprecipitation using antibodies against the endogenous MGA or IgG in HEK293T, A549 and NCI-H23 cells. Around 10 million cells were lysed with NP40 lysis buffer (1% NP40, 150 mmol/L NaCl and 50 mmol/L Tris-HCl pH 8.0) and sonicated by a tip ultrasonic homogenizer. Sonicated cell lysate was first incubated with 2 µg of anti-MGA antibody (Sigma, HPA-042278) or rabbit IgG (Millipore, 12–370) overnight at 4°C and then incubated with mixed Dynabeads A and G (Thermo Fisher) for 2 hours at 4°C. Next, the beads were washed three times with NP40 lysis buffer. Enriched protein was eluted and denatured by NP40 lysis buffer supplemented with LDS sample buffer (Thermo Fisher) and DTT (final concentration: 20 mmol/L).

Quantitative mass spectrometry assays

For immunoprecipitation from HEK293T cells followed by mass spectrometry, we applied the above immunoprecipitation protocol to ~100 million cells and used 20 µg of MGA or IgG antibody. After minimal washing to remove nonspecifically bound proteins, samples were digested with trypsin, labeled with iTRAQ isobaric mass tag reagents (25), mixed together and analyzed by liquid chromatography–mass spectrometry (affinity proteomics). Briefly, the MGA or IgG pulldown samples were washed twice with 200 µL of 50 mmol/L Tris-HCl (pH 7.5), transferred into fresh 1.5 mL Eppendorf tubes, and washed twice with buffer containing 2 M urea/50 mmol/L Tris (pH 7.5). Samples were incubated in 0.4 µg trypsin in 80 µL of 2 M urea/50 mmol/L Tris supplemented with 1 mmol/L DTT for 1 hour at room temperature while shaking at 1,000 × g. After short digest, 80 µL of each supernatant was transferred into new tubes. Beads were washed twice with 60 µL of 2 M urea/50 mmol/L Tris buffer, and these washes were combined with the supernatant. The combined digestion eluates and washes were spun down at 5,000 × g for 2 minutes, transferred into the fresh tubes, and subsequently reduced with 4 mmol/L DTT for 30 minutes at room temperature. Following reduction, samples were alkylated with 10 mmol/L iodoacetamide for 45 minutes in the dark at room temperature. Samples were digested overnight with an additional 0.5 µg of trypsin at room temperature, while shaking. Following overnight digestion, samples were acidified (pH <3) with neat formic acid (FA), to a final concentration of 1% FA. Samples were spun down and desalted on C18 StageTips. Briefly, StageTips were conditioned once with 100 µL of MeOH, once with 100 µL of 50% MeCN/0.1% FA, and twice with 0.1% FA. Sample was loaded, washed twice with 0.1% FA, and eluted with 50 µL of 50% MeCN/0.1% FA. Eluted samples were dried to completion and stored at –80°C.

Desalted peptides were labeled with iTRAQ reagents as follows. Samples were resuspended in 30 µL of dissolution buffer (0.5 TEAB, pH 8.5) combined with 70 µL of ethanol. Once resuspended, samples were mixed with iTRAQ reagent, and incubated at room temperature for 1 hour with shaking. Reaction was quenched with 10 µL of 1 M

Tris-HCl (pH 7.5). Differentially labeled samples were combined, dried down to evaporate ethanol, acidified with neat FA to a final concentration of 1%, and desalted on C18 StageTips as described above.

Labeled and desalted peptides were resuspended in 9 µL of 3% MeCN/0.1% FA and analyzed by online nanoflow liquid chromatography–tandem mass spectrometry (LC-MS/MS) using a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled online to a Proxeon Easy-nLC 1000 (Thermo Fisher Scientific). Briefly, 4 µL of each sample was loaded onto a microcapillary column (360 µm outer diameter × 75 µm inner diameter) containing an integrated electrospray emitter tip (10 µm), packed to approximately 22 cm with ReproSil-Pur C18-AQ 1.9-µm beads (Dr. Maisch GmbH) and heated to 50°C. Samples were analyzed using a 260-minute LC-MS method with the following gradient profile: (min:%B) 0:2; 1:6; 235:30; 244:60; 245:90; 250:90; 251:50; 260:50 (the last two steps at 500 nL/min flow rate). The Q Exactive was operated in the data-dependent mode acquiring HCD MS/MS scans ($r = 17,500$) after each MS1 scan ($r = 70,000$) on the top 12 most abundant ions using an MS1 target of 3×10^6 and an MS2 target of 5×10^4 . The maximum ion time utilized for MS/MS scans was 120 ms; the HCD-normalized collision energy was set to 28; the dynamic exclusion time was set to 20 seconds, and the peptide match and isotope exclusion functions were enabled. Charge exclusion was enabled for charge states that were unassigned, 1 and >7.

Immunoblotting

Cells were lysed by NP40 lysis buffer (1% NP-40, 150 mmol/L NaCl, 50 mmol/L Tris-HCl pH 8.0) supplemented with protease and phosphatase inhibitor (Thermo Scientific, 1861281) and denatured by LDS sample buffer (Thermo Fisher) supplemented with 20 mmol/L DTT. Electrophoresis was performed in 3% to 8% Tris-Acetate gel (for immunoblotting MGA) or 4% to 12% NuPage Bis-Tris gel in Tris-Acetate SDS or MOPS SDS running buffer, respectively. Proteins were transferred to a nitrocellulose membrane (0.2 µm) in Novex Tris-Glycine Transfer Buffer (Thermo Fisher) supplemented with 10% methanol overnight at 4°C at constant voltage of 35 V (for transferring MGA) or 2 hours at 70 V. Images were taken on a LI-COR instrument. Antibodies that were used for immunoblotting include MGA (Sigma, HPA-042278), MYC (Cell Signaling Technology, 13987), MAX (Santa Cruz Biotechnology, sc-197), E2F6 (Santa Cruz Biotechnology, sc-53273), HDAC2 (Cell Signaling Technology, 5113), HDAC4 (Santa Cruz Biotechnology, sc-46672), CBX3 (Sigma, WH0011335M1) and RNF2 (MBL, D139-3).

MGA expression construct

For human MGA (NM_001164273.1) cloning, MGA cDNA sequence was subdivided into three fragments using internal restriction sites (1–3,168 bp; 3,147–6,632 bp; 6,611–9,198 bp). Fragments were amplified by PCR from a cDNA pool using Phusion High-Fidelity DNA Polymerase (Biolabs) following standard protocols. Necessary restriction sites were added to the primer sequences (Supplementary Table S2). MGA fragments were subcloned in the pGEM-T Easy Vector (Promega, A1360) and then cloned into the pLVX-IRES-ZsGreen1 Vector (Clontech Laboratories) for further analyses.

ChIP-seq analysis

Chromatin immunoprecipitation-sequencing (ChIP-seq) assays were performed as previously described (26). Antibodies used include MGA (Sigma, HPA-042278) and c-MYC (Cell Signaling Technology, 13987). The Cell Signaling antibody 13987 (clone ID: D3N8F) was

annotated as an c-MYC-specific antibody during our assays but is now noted to also cross-react with the N-MYC protein (<https://www.cellsignal.com/products/primary-antibodies/c-myc-n-myc-d3n8f-rab-bit-mab/13987>). Based on the RNA-seq results of the A549 cell line from the CCLE project (ref. 24; <https://portals.broadinstitute.org/ccle/>), c-MYC is the MYC family gene that is predominantly expressed (read counts: 18,349) in the lung adenocarcinoma cell line, whereas N-MYC is barely detectable by RNA-seq (read counts: 7, less than 0.1% of c-MYC counts). In addition, siRNA against MYC diminishes the protein signal detected by the antibody (Fig. 4A). Thus, the ChIP-seq and Western blot signal detected by the cell signaling antibody 13987 is specific to c-MYC in our experiments.

The sequencing libraries were prepared using the NEB ChIP-seq library prep kit (NEB, E6200L) and sequenced on the Illumina MiSeq instrument (50-bp single read sequencing). Sequencing reads were aligned by BWA (27) and the binding sites of MGA and MYC were identified by MACS2 “callpeak” function (28). DNA-binding motifs enriched in the MGA binding sites were identified by the Homer *de novo* motif analysis (29). ChIP-seq tracks (bigWig files) were presented in the Integrative Genomics Viewer (30). The Cistrome Analysis Pipeline (31) was used to generate ChIP-seq heat maps and to perform ChIP-seq correlation analysis. The averaged ChIP-seq tags at gene promoter regions were calculated by Homer “annotatePeaks” function (29).

RNA-seq analysis

RNA was extracted using the Qiagen RNeasy kit with on-column DNase I treatment. RNA (500 ng) for each sample was processed with the NEBNext PolyA mRNA Magnetic Isolation Module (NEB #E7490) and further processed with the NEBNext Ultra Directional RNA Library Prep Kit (NEB E7420S). RNA libraries were then sequenced on an Illumina MiSeq (75-bp paired-end sequencing). Sequencing reads were aligned using the STAR pipeline (32) and quantified by the RSEM pipeline (33). Differential gene-expression analysis was performed using the edgeR pipeline (34). Gene set enrichment analysis (GSEA) analysis was performed using the Gene Pattern pipeline (35).

RT-qPCR

Reverse transcription of extracted RNA was carried out using the iScript Reverse Transcription kit (Bio-Rad), and qPCR reactions were performed using the Power SYBR Green PCR MasterMix (Life Technologies) on a CFX384 real-time thermocycler (Bio-Rad), according to the manufacturer's protocols. Primer sequences are available in Supplementary Table S2.

Competitive cell proliferation assay

For MGA overexpression experiments, A549 and NCI-H23 cells were transfected with either pLVX-MGA-Zs-Green or empty vector by Lipofectamine LTX Reagent with PLUS Reagent (Thermo Fisher, 15338100), and were then maintained in regular media for 24 hours before cell sorting (F-Ariall SORP) to select transfected cells by GFP signal. GFP-positive cells were then mixed with parental cells and maintained in regular media. The percentage of GFP-positive cells was counted by the flow cytometry analyzer at days 0, 4, and 6.

Public data set usage

The following data sets were downloaded from ENCODE (36) and used in the study [MAX ChIP-seq in A549 cells, Gene-Expression Omnibus (GEO) accession number: GSM935298; E2F6 ChIP-seq in A549 cells, GEO accession number: GSM1010766].

Accession codes

The newly generated ChIP-seq and RNA-seq data for this study have been deposited to the GEO public data set under the series GSE112188 and GSE112190, respectively.

Results

MGA loss-of-function mutations and deletions in lung adenocarcinomas

MGA has been reported to be a significantly mutated gene in lung adenocarcinomas (20, 37). In the TCGA Pan-Cancer lung adenocarcinoma data set (38), 27 of the 49 MGA mutations are truncating (Fig. 1A). In addition, the MGA gene is subject to copy-number deletions (11/507 cases) but not amplifications (Supplementary Fig. S1A), suggesting that MGA may act as a tumor suppressor. These alterations are complementary to MYC genomic activation, where 42 of 507 (~8%) lung adenocarcinomas acquire amplifications of the MYC gene (Supplementary Fig. S1A; data extracted from the c-Bio portal: <https://www.cbioportal.org/>). As shown in TCGA Pan-Cancer analysis of MYC pathway members including MGA (10), MGA is subject to truncating mutations and copy-number deletions in multiple cancer types including uterine corpus endometrial carcinomas (UCEC, 45/509), colorectal carcinomas (31/526), and stomach adenocarcinomas (STAD, 19/434), suggesting that MGA may act as a tumor suppressor in multiple lineages (Supplementary Fig. S1B).

MGA is part of a noncanonical PRC1 repressive complex

Given the presence of protein-protein interaction domains in MGA, we sought to determine the protein composition of MGA-containing complexes as a clue to MGA function. To do so, we used an anti-MGA antibody bound to beads to immunoprecipitate endogenous MGA from HEK293T cells that are wild-type for the endogenous MGA (validated by Sanger sequencing). As a negative control, the same cell line was treated with nonspecific IgG bound to beads. We analyzed the results based on the enrichments of peptide precipitated by anti-MGA antibodies versus IgG controls (two biological replicates; Fig. 1B and Supplementary Table S1) and identified 84 proteins that are significantly enriched in the MGA immunoprecipitates (adjusted $P < 0.05$). MAX, which is known to be the canonical binding partner of MGA (19), and the MGA protein itself are among the most significantly enriched proteins in this immunoprecipitation (Fig. 1B).

To understand the MGA-associated protein complex in more depth, we performed David pathway analysis of MGA-interacting proteins (39), which revealed that the MGA complex is enriched in factors involved in transcriptional repression (Supplementary Fig. S2A). Our results were consistent with previous literature in the field. We found that MGA interacts with E2F6 and TFDPI, which form a transcriptional repressing dimer (40), with RING1, RNF2, PCGF6, and L3MBTL2, which are core members of the polycomb repressive complex 1 (PRC1; ref. 41), and with the heterochromatin protein CBX3 (also known as HP1- γ), and the histone deacetylase HDAC1 and HDAC2 (Fig. 1B; Supplementary Fig. S2B), all of which are involved in epigenetic and transcriptional repression. The proteins that interact with MGA form a noncanonical PRC1 (ncPRC1)—the PCGF6-PRC1 complex, also known as PRC1-E2F6 (41–44).

To validate the interactome of MGA in the context of lung cancer, we performed immunoprecipitation assays followed by immunoblotting in the lung adenocarcinoma cell lines A549 and NCI-H23, both of which are wild-type for MGA based on RNA-seq results from the CCLE project (ref. 24; <https://portals.broadinstitute.org/ccle/>). We

validated the interaction of endogenous MGA with MAX, E2F6, HDAC2, CBX3, and RNF2 by immunoprecipitating sonicated whole-cell extracts with MGA antibodies and IgG controls followed by immunoblotting with protein-specific antibodies (Fig. 1C). In contrast, another histone deacetylase factor HDAC4, which was not enriched in the MGA immunoprecipitation-mass spectrometry assay, was not detectable in our immunoprecipitation–Western blot validation, consistent with the specificity of our results (Supplementary Fig. S3A). Furthermore, we immunoprecipitated E2F6 and RNF2, separately, using antibodies against the endogenous proteins in NCI-H23 cells and validated their interaction with MGA (Supplementary Fig. S3B). Therefore, our results together with previous studies that identified MGA in the interactomes of E2F6 and PCGF6 (43, 45) defined an MGA-ncPRC1 transcriptional repression complex.

MGA colocalizes with MYC and E2F6 in the genome

To understand the gene regulation function of MGA and its involvement in the MYC pathway, we next performed chromatin immunoprecipitation-sequencing (ChIP-seq) assays using antibodies against endogenous MGA and MYC in the lung adenocarcinoma cell line A549. Both MYC and MGA binding sites, defined by the MACS2 ChIP-seq pipeline using a q -value threshold of < 0.05 (28), are significantly enriched in gene promoter regions (34.5% for MGA, $P < 10^{-15}$, Fig. 2A), as previously reported for MYC (46). Homer *de novo* motif analysis (29) of the 9,049 MGA binding sites identified by MACS analysis shows that MGA recognizes the same E-box DNA sequence (centered at CACGTG) as the MYC protein (Fig. 2B; Supplementary Fig. S4), which was previously suggested by gel-shifting assays (19). Interestingly, the T-box domain DNA motif was not listed as a significant hit in the analysis (Supplementary Fig. S4), suggesting that the T-box domain is not a major driver for MGA recruitment in these experiments.

When we analyzed the ChIP-seq results for MAX and E2F6 from A549 cells derived from the ENCODE project (36), we found that MGA binding sites are enriched for binding of MYC, MAX, and E2F6 (Fig. 2C). Statistical analysis shows that the binding intensity of MGA positively correlated with that of MYC (Pearson correlation: $r = 0.66$), MAX (Pearson correlation: $r = 0.49$), and E2F6 (Pearson correlation: $r = 0.69$) across MGA binding sites (Supplementary Fig. S5A). The majority (~75%) of MGA binding sites are also identified by ChIP-seq of MGA in a separate lung adenocarcinoma cell line NCI-H23 that harbors MYC gene amplification (ref. 24; Fig. 2D and E). The MGA, MYC, MAX, and E2F6 proteins colocalize to the promoter regions of canonical MYC target genes such as *CDK4* and *NME1* (refs. 46, 47; Fig. 2E). ChIP-qPCR assays in NCI-H23 cells using primers targeting promoter regions of the *AURKA* and *CDK4* genes validate the colocalization of MYC and MGA (Supplementary Fig. S5B). Taken together, our results showed that MGA forms part of a noncanonical PRC1 complex with MAX and E2F6, and that this MGA–MAX–E2F6 complex binds to the same loci in the genome as the MYC oncoprotein, suggesting that MGA and MYC regulate a similar set of genes but as part of different complexes.

MGA represses MYC target genes

To interrogate the impact of MGA on gene expression, we cloned MGA cDNA into an overexpression vector linked to ZsGreen (an improved GFP variant) via an Internal Ribosome Entry Site (IRES) sequence, which allows us to use GFP signal to monitor MGA protein expression level (more details are described in Materials and Methods). Two days after transfection, we collected A549 cells carrying the

empty-ZsGreen (control) or MGA-ZsGreen overexpression vector based on positive GFP signal, and immediately performed RNA-seq and MGA ChIP-seq assays. We compared the impact of MGA on gene expression with MGA binding. Based on RNA-seq analysis, we categorized genes into three groups (adjusted P cutoff = 0.05): 625 MGA-repressed genes, 658 MGA-activated genes, and 17,229 genes that are expressed but unaffected by MGA. We then assessed the MGA binding intensity at gene promoters within ± 2 kb from transcription start sites (TSS), which showed an overall increase of MGA binding after MGA overexpression (Fig. 3A). Genes that are repressed by MGA gained an increased level of MGA binding to their promoters after MGA overexpression, compared with genes that are unaffected by MGA, supporting the notion that MGA binds to and represses these genes (Fig. 3A; examples shown in Fig. 3B and Supplementary Fig. S6). Interestingly, we also observed a higher level of MGA binding gained at promoters of MGA-activated genes, compared with unaffected genes, suggesting that MGA may play divergent transcriptional regulatory roles for different sets of genes (Fig. 3A).


GSEA (35) revealed that MYC target genes, which were identified from previous studies (47–50), are downregulated on the expression level in A549 cells overexpressing MGA, compared with the empty control, suggesting that MGA acts as a repressor for MYC target genes (Fig. 3C). In order to validate our finding, we performed RNA-seq in A549 cells with and without siRNA-mediated MYC silencing. GSEA analysis showed that MGA-repressed and MYC-activated genes are involved in the same pathways such as “G₂–M checkpoint,” “MYC targets,” and “Glycolysis” (Supplementary Fig. S7A). Indeed, 44.5% of MGA-repressed genes are activated by MYC (Fig. 3D). In contrast, 8.7% of MGA-activated or 10.2% MGA-unaffected genes can be activated by MYC (Fig. 3D). Most of the MGA-repressed/MYC-activated genes are bound by MGA and E2F6 together, suggesting the role of the PRC1–E2F6 complex in repressing those genes (Supplementary Fig. S7B). Taken together, our results showed that MGA acts as a repressor for the MYC pathway by binding to and repressing genes that are bound and activated by the MYC oncoprotein. We also validated our gene-expression results by RT-qPCR assays in a separate lung adenocarcinoma cell line NCI-H23. Indeed, either MYC silencing or MGA overexpression decreased the expression level of canonical MYC target genes including *CDK4*, *AURKA*, and *NME1* in NCI-H23 cells (Fig. 3E).

MGA is a negative regulator of cancer cell proliferation

Given the antagonistic functions of MYC and MGA in regulating their target genes, we next aimed to assess their respective roles in cancer cell proliferation. Silencing of MYC by siRNA results in a significant reduction in proliferation of A549 and NCI-H23 cells (Fig. 4A and B), consistent with previous reports in other cell lines that MYC acts as a positive regulator for cell proliferation and can be disrupted using siRNA (51). To assess the role of MGA in cell proliferation, we utilized the ZsGreen system and performed competitive cell proliferation assays for A549 and NCI-H23 cells with and without ectopic MGA overexpression. Briefly, cells transfected with the empty-ZsGreen or MGA-ZsGreen vector were collected and counted through GFP-based sorting. The GFP-positive cells were then mixed with the same number of parental A549 or NCI-H23 cells (GFP-negative). Subsequently, the proportion of GFP-positive cells was measured by a flow cytometer over time (including the starting time when the cell populations were mixed; Fig. 4C). We found that, compared with the empty vector control, overexpression of MGA significantly reduced the proliferation rates of A549 and NCI-H23 cells, as measured 4 days and 6 days after seeding the cells (Fig. 4D

Figure 2.

ChIP-seq analyses reveal that MGA colocalizes with MYC and E2F6 in the genome. **A**, Genomic distribution of MYC and MGA binding sites in A549 cells. **B**, Homer *de novo* motif analysis identified the top DNA motif enriched in MGA binding sites identified in A549 cells. **C**, ChIP-seq signal of MGA, MYC, MAX, and E2F6 (A549 cells) at the 9,049 MGA binding sites (top to bottom ranked by MGA ChIP-seq signal ± 2.5 kb centered at each MGA binding site). **D**, Comparison of MGA ChIP-seq binding sites identified in A549 and NCI-H23 cells. **E**, ChIP-seq signal of MGA in A549 and NCI-H23 cells, MYC, MAX, and E2F6 in A549 cells at the *CDK4* and *NME1* loci. The E-box DNA motif (CACGTG) positions are indicated.



and E), suggesting that MGA acts as a repressor for cancer cell proliferation. We also overexpressed the wild-type MGA in the lung adenocarcinoma cell line LXF289 that harbors an MGA truncating mutation [MGA p.Q1067*, based on CCLE database (ref. 24) and validated by Sanger sequencing] and observed a significant reduction in its cell proliferation as well as expression of MYC target genes (Supplementary Fig. S8). MGA-overexpressing NCI-H23 cells did not undergo increased apoptosis, as measured by annexin V/propidium iodide staining. A higher proportion of MGA-overexpressing cells was

observed in the G₁ phase of the cell cycle, as measured by propidium iodide staining in the fixed cells (Supplementary Fig. S9), indicative of cell-cycle arrest or delay induced by MGA overexpression. Immunoblots show that overexpression of MGA has little effect on expression level of the MYC protein (Fig. 4D and E, top), showing that the observed phenotype change is not dependent on modifying MYC expression levels. Our results show that MGA represses cell proliferation in contrast to MYC that is well known to promote cell proliferation.




Figure 3.

ChIP-seq/RNA-seq analyses show that MGA binds to and represses MYC target genes. **A**, Averaged ChIP-seq signal of MGA in A549 cells with and without MGA overexpression at the TSS of genes that are activated, repressed, and unaffected by MGA (based on RNA-seq results in A549 cells with and without MGA overexpression). **B**, ChIP-seq signal of MGA in A549 cells with and without MGA overexpression at the *CDK4* locus. **C**, GSEA of RNA-seq results in A549 cells with and without MGA overexpression showed that MGA-repressed genes are enriched in MYC target genes identified by previous studies. **D**, Percentage of MGA-regulated genes that are activated by MYC (based on RNA-seq results from A549 cells with and without siRNA-mediated MYC silencing). *P* values are derived from Fisher exact tests. **E**, RT-qPCR assays in NCI-H23 cells validated that either silencing MYC or overexpressing MGA decreased the expression level of the MYC target genes *CDK4*, *AURKA*, and *NME1*. Expression level is normalized to controls (siNC or Empty). Error bars, SD.


Discussion

In human development and pathogenesis, MYC functions by binding to and regulating its target genes that are involved in varied biological processes. Activation of the MYC pathway is a key driver for diverse cancer types. MYC can be activated by diverse genomic alterations, which commonly result into upregulation of the target genes and promotes tumorigenesis. For example, germline genetic

variants (52, 53), gene amplification (1), chromosomal translocations (3), superenhancer duplications (4, 5), and activation of the upstream Wnt signaling pathway (54) can result into transcriptional activation of the *MYC* gene. In addition, activation of the RAS pathway also stabilizes MYC on the protein level (55). Furthermore, missense mutations at the amino acid Thr58 block the binding of the E3 ubiquitin ligase FBXW7 to MYC, which enhances the protein stability

Figure 4.

MGA acts as a repressor for cancer cell proliferation. **A**, siRNA-mediated silencing of MYC (verified by immunoblots) decreased the proliferation of A549 cells. Cell number was counted 5 days after transfection and normalized to the negative control siRNA. *P* values are derived from *t* tests. Error bars, SD; **, *P* < 0.01. **B**, Same experiment as **A**, but in NCI-H23 cells. Error bars, SD; ***, *P* < 0.001. **C**, Schematic chart explaining the design of competitive cell proliferation assays. A549 and NCI-H23 cells were first transfected with empty-ZsGreen control or MGA-ZsGreen vector. The transfected cells were collected based on GFP signal and mixed with parental cells at 1:1 ratio. The percentage of GFP-positive cells was then counted over time. **D**, MGA overexpression (verified by immunoblots) decreased the proliferation of A549 cells. The percentage of GFP-positive cells was counted 4 and 6 days after seeding the cells and normalized to the empty-ZsGreen control. *P* values are derived from *t* tests. Error bars, SD; *, *P* < 0.05; ***, *P* < 0.001. **E**, Same experiment as **D**, but in NCI-H23 cells. Error bars, SD; **, *P* < 0.01; ***, *P* < 0.001.



of MYC and increases its protein abundance in cancer cells bearing this mutation (56).

Here, we provide more analysis of another mechanism that regulates the MYC pathway without altering the transcription or protein level of MYC. Previous *in vitro* gel-shifting and luciferase reporter assays showed that MGA, another MAX-interacting protein, recognizes the E-box motif and represses reporter expression driven by

MYC (19). We integrate ChIP-seq and RNA-seq assays and show that MGA directly binds to and represses genes that are activated by the MYC oncoprotein on the genome wide scale. In addition, we show that overexpression of MGA inhibits proliferation of lung adenocarcinoma cell lines, which is complementary to previous finding that MGA represses cellular transformation, as measured in rat embryo fibroblasts (19). In tumor samples, the MGA gene is subject to truncating

mutations and copy-number deletions in multiple cancer types. Our experimental results, complemented by cancer genomics data, suggest that MGA acts as a tumor suppressor by inhibiting the MYC pathway in lung adenocarcinoma. In addition to cell proliferation and transformation, activation of the MYC oncogene has been associated with metastasis in diverse cancer types including lung cancer. For instance, genetically engineered MYC-driven mouse small cell lung cancers often metastasize to livers (57). Given the antagonistic functions of MYC and MGA in gene regulation, it is possible that MGA also plays a role in metastasis, which needs future investigations.

The antagonistic roles of MYC and MGA in gene regulation could be due to their interacting protein complexes. MYC interacts with different types of transcription activators including TRRAP to increase the histone acetylation at gene promoters and P-TEFB to release the paused RNA polymerase II for the target genes (13, 15). Previous studies immunoprecipitating E2F6 and PCGF6 identified MGA as an interacting protein (43, 45). Our immunoprecipitation of the endogenous MGA followed by mass spectrometry results provided a complete interactome of MGA and showed that, in addition to E2F6 and PCGF6, MGA physically interacts with most members of the noncanonical PRC1–the PCGF6–PRC1 complex, including multiple epigenetic and transcriptional repressors such as RING1, RNF2, CBX3, HDAC1, and HDAC2, highlighting the importance of the PCGF6–PRC1 complex in the MGA pathway. The PCGF6–PRC1 complex can repress target genes by H2A monoubiquitination, H3K9 dimethylation, H3K27 trimethylation, and histone deacetylation (41, 44), which may explain the gene repression role of MGA. It has been recently reported that the association with RNF2 and the subsequent H2A monoubiquitination are required for the silencing effect of MGA in pluripotent stem cells (58). The PCGF6–PRC1 complex has been described to play important roles in the maintenance of embryonic stem cells and suppression of dendritic cells (58, 59). Further analysis is needed to assess whether the formation of the MGA–PCGF6–PRC1 complex is required for the repression effect of MYC target genes. Our data suggest that MGA may serve as a sequence-specific DNA-binding factor for recruiting the PCGF6–PRC1 complex to specific targets of the genome, which is in agreement with recent findings that MGA knockdown impairs the binding of PCGF6 to target genes in HEK293 cells and mouse embryonic stem cells (58, 60). It remains unanswered which domain or domains of MGA is or are required for the recruitment of the complex and the repression of its target genes. In addition, given our observation that MGA and MYC share a large set of binding sites and target genes, one interesting question that remains unanswered is whether the MGA complex plays an antagonistic role to the MYC complex in the release of RNA polymerase II from the promoter regions of their target genes (15).

Both MYC and MGA function by interacting with the MAX protein. Our study proposes a working model in which the expression level of MYC target genes is tightly regulated by a balance between the MYC/MAX and MGA/MAX complexes including their associated epigenetic and transcriptional regulators. MYC acts as an accelerator and MGA acts as a brake for driving the expression of their target genes. Either overexpression of MYC or silencing of MGA breaks this balance, leading to aberrant overexpression of the target genes, activation of oncogenic pathways, and tumorigenesis. Our results suggest that MGA binds to and represses MYC target genes. Additionally, the MGA protein may compete with MYC for the interaction with MAX and limit the abundance of the MYC/MAX complex in cells, which may serve as an additional mechanism in suppressing MYC target genes. Interestingly, the MAX gene is also subject to homozygous inactivating mutations and deletions in small cell lung cancer and gastrointestinal

stromal tumors, which results into a complete loss of the MAX protein in those cancers (61, 62). One important remaining question is how loss of MAX alters the balance between MYC and MGA and affects their target genes.

The expansion of alterations in the MYC pathway offers the hope of expanding therapeutic options for lung cancer and beyond. Lung cancer is the leading cause of cancer-related mortality worldwide, whereas around 40% of cases are lung adenocarcinomas (63). Genomic activation of the receptor tyrosine kinases (RTK) and their downstream signal transduction pathways is a key driver for lung adenocarcinomas. Inhibitors of RTK such as EGFR and ALK have also greatly benefited the treatment of patients bearing these alterations (64, 65). However, effective and durable therapy of lung adenocarcinoma will likely require combination treatment. The discovery of MGA mutations, along with the previous finding of MYC amplification in lung adenocarcinomas, now defines a new pathway in complementation to the RTK/RAS/RAF pathway, a MYC/MAX/MGA pathway. Roughly 15% of lung adenocarcinoma cases have been detected to harbor either MYC amplification or MGA loss-of-function alterations. Genomic alterations of the MYC/MAX/MGA pathway contribute to epigenetic and transcriptional dysregulation in the genome, which may provide opportunities for novel therapeutic interventions that are targeting epigenetic modification and transcription.

Disclosure of Potential Conflicts of Interest

D. Cai is employed at Johnson and Johnson. M. Meyerson is Scientific Advisory Board chair at Origimed and reports receiving commercial research grants from Bayer, Ono, and Janssen. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: P.S. Choi, M. Sanchez-Cespedes, M. Meyerson, X. Zhang
Development of methodology: P. Llabata, Y. Mitsuishi, M. Torres-Diz, S.A. Carr, X. Zhang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Llabata, Y. Mitsuishi, N.D. Udeshi, Z. Wu, J. Zhou, Y. Liu, S.A. Carr, X. Zhang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Llabata, Y. Mitsuishi, P.S. Choi, J.M. Francis, N.D. Udeshi, L. Golomb, T. Svinkina, S.A. Carr, X. Zhang

Writing, review, and/or revision of the manuscript: P. Llabata, Y. Mitsuishi, J.M. Francis, M. Torres-Diz, N.D. Udeshi, S.A. Carr, M. Sanchez-Cespedes, M. Meyerson, X. Zhang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Cai, E. Aguilera-Jimenez, X. Zhang

Study supervision: M. Sanchez-Cespedes, M. Meyerson, X. Zhang

Acknowledgments

We acknowledge research support from the Lung Cancer Research Foundation Fund (X. Zhang), the 2015 AACR–John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship (X. Zhang), NCI grants R35CA197568 (M. Meyerson), the Norman R. Seaman Endowment Fund (M. Meyerson), the Spain MINECO grants SAF-2014-54571-R (M. Sanchez-Cespedes) and BES-2015-072204 (P. Llabata), the Fundación Científica Asociación Española Contra el Cancer grant GCB14-2170 (M. Sanchez-Cespedes), NCI Clinical Proteomic Tumor Analysis Consortium grants NIH/NCI U24-CA210986 (to S.A. Carr) and NIH/NCI U01 CA214125 (to S.A. Carr), and the European Association for Cancer Research Travel fellowship (P. Llabata). M. Meyerson is an American Cancer Society Research Professor.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 25, 2019; revised November 25, 2019; accepted December 18, 2019; published first December 20, 2019.

References

- Beroukhi R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;463:899–905.
- Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet* 2013;45:1134–40.
- Batley J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. *Cell* 1983;34:779–87.
- Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe J-S, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. *Genes Dev* 2013;27:2648–62.
- Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. *Nat Genet* 2016;48:176–82.
- Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat Med* 2014;20:1130–7.
- Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Mol Cell Biol* 1999;19:1–11.
- Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer* 2008;8:976–90.
- Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. *Science* 2016;352:227–31.
- Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across The Cancer Genome Atlas. *Cell Syst* 2018;6:282–300.
- Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. *Nature* 1992;359:423–6.
- Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science* 1991;251:1211–7.
- Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. *J Biol Chem* 2002;277:40156–62.
- McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. *Cell* 1998;94:363–74.
- Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. *Cell* 2010;141:432–45.
- Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. *Mol Cell* 2013;49:843–57.
- Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. *Cell* 1995;80:767–76.
- Hurlin PJ, Quéva C, Koskinen PJ, Steingrímsson E, Ayer DE, Copeland NG, et al. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. *EMBO J* 1995;14:5646–59.
- Hurlin PJ, Steingrímsson E, Copeland NG, Jenkins NA, Eisenman RN. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif. *EMBO J* 1999;18:7019–28.
- De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Brusca A, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. *Leuk Lymphoma* 2013;54:1087–90.
- The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543–50.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012;2:401–4.
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013;6:pl1.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012;483:603–7.
- Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in *Saccharomyces cerevisiae* using amine-reactive isobaric tagging reagents. *Mol Cell Proteomics* 2004;3:1154–69.
- Zhang X, Cowper-Salari R, Bailey SD, Moore JH, Lupien M. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. *Genome Res* 2012;22:1437–46.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754–60.
- Zhang Y, Liu T, Meyer CA, Eeckhoutte J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* 2008;9:R137.
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 2010;38:576–89.
- Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol* 2011;29:24–6.
- Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. *Genome Biol* 2011;12:R83.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
- Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 2011;12:323.
- Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. *Methods Mol Biol* 2014;1150:45–79.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
- ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, et al. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012;489:57–74.
- Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat Genet* 2016;48:607–16.
- Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. *Cell* 2018;173:371–85.
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44–57.
- Morkel M, Wenkel J, Bannister AJ, Kouzarides T, Hagemeyer C. An E2F-like repressor of transcription. *Nature* 1997;390:567–8.
- Trojer P, Cao AR, Gao Z, Li Y, Zhang J, Xu X, et al. L3MBTL2 protein acts in concert with PcG protein-mediated monoubiquitination of H2A to establish a repressive chromatin structure. *Mol Cell* 2011;42:438–50.
- Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, Steensgaard P, et al. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. *J Biol Chem* 2005;280:1199–208.
- Ogawa H, Ishiguro KI, Gaubatz S, Livingston DM, Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. *Science* 2002;296:1132–6.
- Qin J, Whyte WA, Anderssen E, Apostolou E, Chen HH, Akbarian S, et al. The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development. *Cell Stem Cell* 2012;11:319–32.
- Gao Z, Zhang J, Bonasio R, Strino F, Sawai F, Parisi F, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. *Mol Cell* 2012;45:344–56.
- Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proc Natl Acad Sci U S A* 2006;103:17834–9.
- Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. *Proc Natl Acad Sci U S A* 2002;99:6274–9.
- Schuhmacher M, Kohlhuber F, Hölzel M, Kaiser C, Burtscher H, Jarsch M, et al. The transcriptional program of a human B cell line in response to Myc. *Nucleic Acids Res* 2001;29:397–406.
- Yu D, Cozma D, Park A, Thomas-Tikhonenko A. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. *Ann N Y Acad Sci* 2005;1059:145–59.

50. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome Biol* 2003;4:R69.
51. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. *EMBO Rep* 2007;8:70–6.
52. Pomerantz MM, Ahmadiyah N, Jia L, Herman P, Verzi MP, Doddapaneni H, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat Genet* 2009;41:882–4.
53. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. *Mol Cell Biol* 2010;30:1411–20.
54. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. *Science* 1998;281:1509–12.
55. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev* 2000;14:2501–14.
56. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. *EMBO J* 2004;23:2116–25.
57. Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. *Cancer Cell* 2017;31:270–85.
58. Endoh M, Endo TA, Shinga J, Hayashi K, Farcas A, Ma KW, et al. PCGF6-PRC1 suppresses premature differentiation of mouse embryonic stem cells by regulating germ cell-related genes. *eLife* 2017;6:pii:e27970.
59. Boukhaled GM, Cordeiro B, Deblois G, Dimitrov V, Bailey SD, Holowka T, et al. The transcriptional repressor polycomb group factor 6, PCGF6, negatively regulates dendritic cell activation and promotes quiescence. *Cell Rep* 2016;16:1829–37.
60. Stielow B, Finkernagel F, Stiewe T, Nist A, Suske G. MGA, L3MBTL2 and E2F6 determine genomic binding of the non-canonical polycomb repressive complex PRC1.6. *PLoS Genet* 2018;14:e1007193.
61. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. *Cancer Discov* 2014;4:292–303.
62. Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, et al. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. *Nat Commun* 2017;8:14674.
63. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359–86.
64. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693–703.
65. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–57.